Purpose: Review and systematization of modern ideas about the mechanisms of the development of the effects of ionizing radiation in medium doses on a living organism in order to assess the need and possibility of using pharmaceutical agents suitable for modification purposes, about research methods in experiment; stimulation of discussion on the issue under consideration. Results: the current understanding of the genesis of radiation effects from irradiation at medium doses in the range of 0.2-1 Gy as a subject of modification with antiradiation agents is considered. Conclusions: The systematic nature of modern knowledge about the genesis of radiation effects from low-power irradiation in medium doses of the range 0.2-1 Gy, heterogeneity and mixing of mechanisms can be considered as a basis for the use of antiradiation agents with different properties and aimed at target (direct) and non-target (indirect) ) the effect of radiation. One of the problems of using and predicting the radioprotective efficiency of the PLC is the poor development of methods for establishing correlations between the indicators of increased radioresistance (without irradiation) with the actual antiradiation effect.

Purpose: Review and systematization of data on the development of studies of drugs intended for protection against radiation in medium doses, assessment of the latest proposals and directions of pharmacological influence on radiation effects, incitement to discussion on the issue under consideration. Results: An analysis of domestic and foreign literature for the period of the 70–90s of the twentieth century and the latest period in relation to the prevention of tissue reactions and long-term effects of low-dose low-power irradiation was carried out, classes (groups) and samples of pharmaceuticals used were considered. Conclusions: 1. Very diverse previously proposed pharmaceuticals are still suitable, acting on various mechanisms of the genesis of the consequences of exposure to medium doses. 2. In recent years, substances (drugs) with receptor action, including genetically engineered products, as well as gene therapy agents, have been of primary interest, but they have been little studied as the means of choice due to their status as demonstration samples for use at medium doses. 3. Drugs of choice, made on the basis of many considerations over 30 years ago, until a replacement not be found.